Economic analyses of clinical trials in cancer: Are they helpful to policy makers?

Although clinical trials are being used to evaluate economic outcomes of new agents, there are methodological problems. Decisions based on these analyses may lead to inefficient use of medical resources.

[1]  C. Bennett,et al.  Economic analysis in phase III clinical cancer trials. , 1994, Cancer investigation.

[2]  G D Long,et al.  Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. , 1993, Blood.

[3]  G. Rosner,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.

[4]  J. Crawford,et al.  The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. , 1993, European journal of cancer.

[5]  B. Coiffier,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. , 1992, Blood.

[6]  K. Shannon.  Genetic alterations in leukemia: events on a grand scale. , 1992, Blood.

[7]  R. Advani,et al.  Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for Lymphoma , 1992, Annals of Internal Medicine.

[8]  G A Colditz,et al.  Cost-Effectiveness and Cost-Benefit Analyses in the Medical Literature , 1992, Annals of Internal Medicine.

[9]  C. Bennett,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. , 1992, Annals of internal medicine.

[10]  M F Drummond,et al.  Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues , 1991, International Journal of Technology Assessment in Health Care.

[11]  J. Armitage,et al.  Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. , 1991, The New England journal of medicine.

[12]  S. Greenfield,et al.  The relation between resource use and in-hospital mortality for patients with acquired immunodeficiency syndrome-related Pneumocystis carinii pneumonia. , 1990, Archives of internal medicine.

[13]  Edward L. Hannan,et al.  Investigation of the Relationship Between Volume and Mortality for Surgical Procedures Performed in New York State Hospitals , 1989 .

[14]  S. Finkler.  The distinction between cost and charges. , 1982, Annals of internal medicine.